This effect had been previously reported in the context of T-ALL [38] and, interestingly, is not shared in KMT2A-rearranged leukemias by Menin-1 inhibitors, which repress FLT3 expression by inhibiting transcriptional activators such as MEIS1 [58]. The gene discussed is FLT3; the disease is leukemia.